MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

Several randomized trials have demonstrated non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations can achieve favorable clinical outcomes on treatment with EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation is considered as a predictive mark...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Li, Jiayu, Li, Xuefei, Ren, Shengxiang, Chen, Xiaoxia, Zhang, Yishi, Zhou, Fei, Zhao, Mingchuan, Zhao, Chao, Chen, Xiu, Cheng, Ningning, Zhao, Yinmin, Zhou, Caicun, Hirsch, Fred R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2014
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4202169/
https://ncbi.nlm.nih.gov/pubmed/25277203
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller